Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed / Refractory Acute Myeloid Leukemia

Leukemia

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed / refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed / refractory AML
Leukemia
III
Strickland, Stephen
NCT03616470
VICCHEM2060

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Kidney (Renal Cell)

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.
Kidney (Renal Cell)
III
Beckermann, Kathryn
NCT03937219
VICCURO1938

Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630 / KEYNOTE-630)

Miscellaneous

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).
Miscellaneous
III
Gibson, Mike
NCT03833167
VICCHN18177

Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

Multiple Cancer Types

This phase II trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Breast, Esophageal, Gastric/Gastroesophageal, Lung, Non Small Cell, Pancreatic, Small Cell
II
Mayer, Ingrid
NCT03694249
VICCMD1854

Nintedanib, Idarubicin Hydrochloride, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

This phase I / II trial studies the side effects of nintedanib, idarubicin hydrochloride, and cytarabine and to see how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Nintedanib may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as idarubicin hydrochloride and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib, idarubicin hydrochloride, and cytarabine may work better in treating patients with acute myeloid leukemia.
Leukemia
I/II
Strickland, Stephen
NCT02665143
VICCHEM1689

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Multiple Cancer Types

This randomized phase III trial studies how well Lactobacillus plantarum works in preventing acute graft versus host disease in children undergoing donor stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease in children, adolescents, and young adults undergoing donor stem cell transplant.
Gastrointestinal, Pediatrics
III
Kitko, Carrie
NCT03057054
COGACCL1633

Ruxolitinib in Preventing Breast Cancer in Patients with High Risk and Precancerous Breast Lesions

Breast

This phase II trial studies how well ruxolitinib before surgery works in preventing breast cancer in patients with high risk and precancerous breast conditions. Ruxolitinib may changes the breast cell when administered to participants with precancerous breast conditions. Ruxolitinib may stop the growth of cells by blocking some of the enzymes needed for cell growth.
Breast
II
Meszoely, Ingrid
NCT02928978
VICCBRE1904

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Dermatologic

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD
Dermatologic
III
Zic, John
NCT02811783
VICCDERM1798

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

Sarcoma

Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and / or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing / Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Sarcoma
II
Keedy, Vicki
NCT02048371
VICCSAR1483

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867 / KEYNOTE-867)

Multiple Cancer Types

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC). The primary study hypotheses are: 1. SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution), and 2. SBRT plus pembrolizumab prolongs Overall Survival (OS) compared to SBRT plus placebo.
Lung, Non Small Cell
III
Osmundson, Evan
NCT03924869
VICCTHO1940

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: